Cerebellar degeneration

Summary

Cerebellar degeneration (MONDO:0022687) is a disease and 3 clinical trials. A subtype of cerebellar disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebellar degeneration
Mondo ID	MONDO:0022687
DOID	DOID:1443
NCIT	C84624
SNOMED CT	95646004
UMLS	C0262404
MedGen	75496
Anatomy (UBERON)	UBERON:0002037
Is cancer (heuristic)	no

Also known as: cerebellar Degeneration · cerebellar degeneration · cerebellum neurodegenerative disease · neurodegenerative disease of cerebellum

Disease family

This is a subtype of cerebellar disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebellar disorder › cerebellar degeneration

Related subtypes (4): cerebellar neoplasm, Miller Fisher syndrome, Dandy-Walker syndrome, Behrens Baumann dust syndrome

Subtypes (2): cerebellar ataxia, paraneoplastic cerebellar degeneration

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00716066	PHASE2	ACTIVE_NOT_RECRUITING	Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
NCT07500103	Not specified	RECRUITING	Spatiotemporal Entrainment Neuromodulation Targeting Cerebello-Cerebral Circuits to Enhance Cognitive and Social Rehabilitation in Cerebellar Diseases
NCT05436262	Not specified	COMPLETED	Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHEMBL15720	0	1